Insitro, Inc. Overview
Pro stress-test →Insitro is an AI therapeutics company built on causal biology that generates an integrated, multimodal corpus of human and cellular data and analyzes it with machine learning to reveal how disease begins, progresses, and can be resolved. The company is building a different kind of drug company to bring better drugs faster to patients who can benefit most through the power of machine learning and data at scale to decode the complexities of biology.
Strategic Profile
Pro stress-test →Insitro completed its full stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics with an integrated approach that accelerates the generation of clinic-ready assets while reducing late-stage development risk. The company applies its approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience.
Competitive Landscape
Pro stress-test →Exscientia, Numerion Labs, Verge Genomics, and Recursion Pharmaceuticals are competitors of Insitro. Insitro differentiates through its causal biology approach, full-stack platform spanning multiple modalities, and strategic pharma partnerships. Insitro stands 1st in terms of total funding among its competitors.
Industry Context
Insitro, Inc. operates in AI-enabled drug discovery platforms.
Key facts
Founded: 2018 · Headquarters: South San Francisco, US · Employees: 254 · Revenue: N/A · Market cap: N/A